In the ZUMA-6 clinical trial, the anti-CD19 CAR T cell product axi-cel combined with the anti-PD-L1 monoclonal antibody atezolizumab for the treatment of r/r DLBCL showed overall feasibility; however, cases of severe CRS and ICANS were reported [82]. The gene discussed is CD19; the disease is congenital rubella syndrome.